Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

preview_player
Показать описание
Dr Esther Oliva reviews the latest key data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML – followed by expert interviews on what they might mean for clinical practice.

---------------
This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

#MyelodysplasticSyndromes
#AcuteMyeloidLeukaemia
#Hematology
#hematologicalmalignancies
#HRMDS
#AML
#Oncology
#MedEd
#Cancer
#EHA2022
  1. Touch Medical Media
Рекомендации по теме
Higher-risk MDS and 0:57:07

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Higher-risk MDS and 0:33:29

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

Understanding Higher Risk 1:13:29

Understanding Higher Risk MDS and Transtion to AML

Management of high-risk 0:01:23

Management of high-risk newly diagnosed MM

CPX-351 plus venetoclax 0:02:11

CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AML

High Risk MDS 1:32:06

High Risk MDS Treatment Strategies

Immunomodulation with pomalidomide 0:06:11

Immunomodulation with pomalidomide in AML and high-risk MDS

Unmet needs in 0:02:02

Unmet needs in high-risk MDS and future therapeutic strategies

Addressing Current Questions 1:59:15

Addressing Current Questions and Controversies in the Management of Myelofibrosis

The current challenges 0:00:59

The current challenges facing high-risk MDS treatment

How serious a 0:03:38

How serious a cancer is MDS? What is the prognosis for MDS?

Advancements in clinical 0:02:07

Advancements in clinical trials for high-risk newly diagnosed multiple myeloma

MDS - AML 0:50:26

MDS - AML - 2020 Spring Virtual Conference: When MDS becomes AML - for High-Risk MDS Patients

Sabatolimab plus HMAs 0:04:47

Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML

Expert Video Report 0:06:53

Expert Video Report on Acute Myeloid Leukemia and high risk MDS from ASH 2020

Uma Borate: Evaluating 0:04:32

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Phase II Trial 0:07:52

Phase II Trial of Azacitidine Versus Azacitidine + Vorinostat (Newly Diagnosed AML or High-Risk MDS)

Community Perspectives on 1:32:49

Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome

What's New in 0:51:49

What's New in MDS May 19 2021

Low Risk vs 0:55:44

Low Risk vs High Risk MDS - What's the Difference?

Vosaroxin and Decitabine 0:08:01

Vosaroxin and Decitabine in Newly Diagnosed Older Patients with AML and High Risk MDS

New Directions in 0:47:17

New Directions in Treating Multiple Myeloma in the Era of Novel Agents

Advancing the treatment 0:31:41

Advancing the treatment of MDS and AML: An update from ASH 2021

Venetoclax with decitabine 0:02:05

Venetoclax with decitabine for high-risk AML and MDS

Комментарии
Автор

My dad has just been diagnosed 3 weeks ago with MDS. He was supposed to start the vidaza 2 weeks ago but Drs didn’t get things in order before Thanksgiving so he had his first appt today 11/28/22 in which once they did bloodwork he was admitted immediately into hospital for transfusion bc his platelets were at 13, 000 and his hemoglobin was 5.3. We really have no idea exactly what is going on. The appt with the oncologist was not informative at all and he said the entire bone marrow report was not back then so his tx may change ones it’s all back. His resting heart rate is 105/115. That is not normal. Where do we go from here?!?

RiouxGrandz